Funded Biotechnology Startups in Melbourne
Melbourne's biotechnology sector has produced at least 11 disclosed funding events between November 2022 and November 2025, spanning pre-seed through Serie…
Melbourne's biotechnology sector has produced at least 11 disclosed funding events between November 2022 and November 2025, spanning pre-seed through Series B alongside several unclassified rounds. The dataset is anchored by Telix Pharmaceuticals' $431M raise in July 2024, which stands well above every other entry. Excluding that outlier, disclosed round sizes range from $2M to $40M — Mesoblast closed $40M in April 2023, Prota Therapeutics took $21M in January 2024, and RAGE Biotech completed a $19M Series A in November 2025, the most recent event on record.
Activity has been consistent across the period, with at least two closes in each calendar year from 2022 through 2025. Round structures vary considerably: five of the 11 raises carry no labeled stage, while the remaining six include pre-seed, seed, Series A, and Series B designations. One round — Cell Bauhaus's Pre-Seed in October 2024 — lists an undisclosed amount.
Most recent rounds
11 shownRelated listings
Frequently asked
What is the largest disclosed round among these Melbourne biotech companies?
Telix Pharmaceuticals raised $431M in July 2024 — a Series Unknown round that dwarfs every other entry in the dataset. The next largest are Mesoblast at $40M (April 2023) and Prota Therapeutics at $21M (January 2024).
Which company closed the most recent funding round?
RAGE Biotech closed a $19M Series A in November 2025, making it the most recent event in the dataset. Propanc and Ena Respiratory both raised in 2025 as well, in August and February respectively.
What funding stages appear most often in this segment?
Five of the 11 rounds are classified as Series Unknown, the most common designation. Series B and Seed each appear twice — Kinoxis Therapeutics and Aravax at Series B; Nutromics and Tiny Bright Things at Seed. Series A and Pre-Seed each appear once.
Which companies raised Series B rounds, and how large were they?
Aravax closed a $20M Series B in December 2022 and Kinoxis Therapeutics closed a $10M Series B in August 2024. Both rounds fall in the mid-range for the dataset, excluding the Telix outlier.
Are there early-stage companies with recent raises in this list?
Cell Bauhaus completed a Pre-Seed round in October 2024 at an undisclosed amount. Tiny Bright Things and Nutromics raised Seed rounds of $2M and $7M in late 2022 and mid-2023, respectively.
How active has Melbourne biotech funding been year over year across this dataset?
The 11 rounds span November 2022 through November 2025, with at least two rounds per calendar year. 2024 saw the most activity with four closes — Telix, Kinoxis Therapeutics, Prota Therapeutics, and Cell Bauhaus — while 2025 already shows three closes through November.
Know which startups just got funded. Every week.
Fresh funding rounds, new companies, and the sectors moving fastest — in your inbox every Monday morning.
Free. Sent every Monday. Unsubscribe anytime.